Sentence examples for sustaining progression from inspiring English sources

As a result of these conditions (more details are given in Figure 13), persistent inflammatory reaction and chronic activation of the wound healing response will occur, sustaining progression of fibrogenesis to the end-point of cirrhosis [ 74- 83].

The author found, between 15.8 and 42.2 % of patients experienced sustained progression based on the definitions using EDSS as the outcome, but nearly 50%% of these patients failed to maintain sustained progression for the duration of follow-up.

The most essential requirement for a valid MRI outcome measure is that its findings are predictive of future clinical outcome, especially sustained progression in disability.

These species damage DNA, producing the mutations that initiate tumours and sustain progression [ 1].

92 Results from the clinical effectiveness AFFIRM trial 93 are very favorable, with Natilizumab reducing the risk of sustained progression of disability by 42%, with the cumulative probability of progression being 17% compared to 29% in the placebo group.

The risk of 24-week sustained progression of disability was also reduced significantly among patients receiving DMF BID (29%) and TID (32%) compared with patients in the placebo group.

The risk of 12-week sustained progression of disability over 2 years was reduced significantly among patients receiving DMF BID (32%) and TID (30%) compared with patients in the placebo group.

In the AFFIRM study, 23 Tysabri® (NA); administered to 627 patients with RRMS at a dose of 300 mg every four weeks for more than two years, produced a reduction of sustained progression of disability by 42%.

More recent findings [ 21] suggest that even a consistent effect of on-study relapses on subsequent "sustained progression" could not be interpreted as evidence for a link between relapse frequency and the accumulation of true, unremitting disability.

In a subgroup analysis that excluded patients on natalizumab, the cumulative probability of progression was 10% for the 10 patients in the PLP10 group and 70% for the 12 patients in the placebo group, representing a relative 86% decrease in the risk of the sustained progression of disability in the PLP10 group (unadjusted log-rank p=0.006; adjusted HR, 0.11; 95% CI 0.01 to 0.97, p=0.047).

At 2 years, the cumulative probability of disability progression was 10% in the PLP10 group and 70% in the placebo group, which represents a decrease of 60% points or a relative 86% decrease in the risk of the sustained progression of disability within the PLP10 group (adjusted HR, 0.11; 95% CI 0.01 to 0.97, p=0.047).